<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180221038821N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-02-05</date_registration>
      <primary_sponsor>Gonabad University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of sesame oil and 1% silver sulfadiazine ointment on the pain, healing and scarring of burn wounds</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of sesame oil and 1% silver sulfadiazine ointment on the pain, healing and scarring of burn wounds</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/68252</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The patients were first selected by the available method and then divided into two groups of sesame oil and silver ointment by using 4 permutation blocks. In this method, the sesame oil group was coded with the letter A and the silver ointment group was coded with the letter B. The six possible states in the blocks included ABAB, BBAA, AABB, BABA, AAAA, BBBB, and each block was assigned a number. For every four selected people, a number will be selected according to the list, and people will be assigned to two groups of sesame oil and silver ointment in this way, Blinding description: The emergency medicine doctor who will confirm the recovery of the patients will not know about the grouping of the patients.
The data analyst will also be unaware of the grouping of patients.</study_design>
      <phase>3</phase>
      <hc_freetext>Burn.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Sesame oil group: For the sesame oil group, the burn wound dressing with sesame oil will first be washed with sodium chloride for washing and exposed to the open air for 5 minutes until it dries completely. Then, the wound area is smeared with 2 ml of sesame oil (for 10 square centimeters of the wound) and the surface of the wound is covered with freezer plastic (to absorb more sesame oil) and then it will be bandaged. Sesame oil used in this notice will be completely natural and without preservatives with standard devices from a local store and will be prepared under supervision. It should be noted that this extract is 100% oily and in addition to being free of water molecules, it also contains antimicrobial compounds that prevent the growth of microbial agents in this extract. Nevertheless, in order to ensure the negativity of the microbial culture, random samples of the extract prepared in the microbial culture media of blood agar, chocolate agar, eosin methylene blue, Kant agar plate, lauryl sulfate broth and selected culture media for the investigation of yeasts and fungi will be used. Intervention 2: Intervention group: Silversulfadiazine 1% group: Dressing the burn wound first, the wound area will be washed with normal saline for washing and exposed to the open air for 5 minutes until it dries completely. Then the wound will be smeared with 1% silver sulfadiazine ointment and covered with freezer plastic and bandaged. One percent silver sulfadiazine ointment of Iran Najo Pharmaceutical Company will also be used for this group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Sampling has not been done yet</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Iman Ghorbany Moghaddam</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No9, Behesht Street, Emam Sajjad Blvd, Gonabad Town</address>
        <city>Gonabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9691647161</zip>
        <telephone>+98 51 5722 0576</telephone>
        <email>imanghorbany135213@gmail.com</email>
        <affiliation>Gonabad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Moosa Sajjadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Asian Roads, Gonabad University of Medical Sciences</address>
        <city>Gonabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9691793718</zip>
        <telephone>+98 51 5722 0576</telephone>
        <email>sajjadi1975@gmail.com</email>
        <affiliation>Gonabad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Informed consent to participate in the study
Age 20-60 years
First and second degree burns with an extent of 1-10%
Burns due to contact with a heat source or liquids</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Sesame oil allergy
Confirmation of the need for hospitalization of the patient by the doctor
Taking painkillers and NSAIDs orally or topically until the first visit to the treatment center
Background diseases such as anemia, diabetes, cardiovascular diseases, malignancy and immune system defects
Abnormal hemoglobin and total protein
More than 6 hours passed from the time of the burn to the time of going to the medical center</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z73.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Burn-out</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Sesame oil group: For the sesame oil group, the burn wound dressing with sesame oil will first be washed with sodium chloride for washing and exposed to the open air for 5 minutes until it dries completely. Then, the wound area is smeared with 2 ml of sesame oil (for 10 square centimeters of the wound) and the surface of the wound is covered with freezer plastic (to absorb more sesame oil) and then it will be bandaged. Sesame oil used in this notice will be completely natural and without preservatives with standard devices from a local store and will be prepared under supervision. It should be noted that this extract is 100% oily and in addition to being free of water molecules, it also contains antimicrobial compounds that prevent the growth of microbial agents in this extract. Nevertheless, in order to ensure the negativity of the microbial culture, random samples of the extract prepared in the microbial culture media of blood agar, chocolate agar, eosin methylene blue, Kant agar plate, lauryl sulfate broth and selected culture media for the investigation of yeasts and fungi will be used.</i_keyword>
      <i_keyword>Intervention group: Silversulfadiazine 1% group: Dressing the burn wound first, the wound area will be washed with normal saline for washing and exposed to the open air for 5 minutes until it dries completely. Then the wound will be smeared with 1% silver sulfadiazine ointment and covered with freezer plastic and bandaged. One percent silver sulfadiazine ointment of Iran Najo Pharmaceutical Company will also be used for this group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Wound healing time. Timepoint: After confirming the healing of the wound by an emergency medicine specialist. Method of measurement: Questionnaire (Day).</prim_outcome>
      <prim_outcome>The scar left by the wound. Timepoint: After confirming the healing of the wound by an emergency medicine specialist. Method of measurement: Beitz-Johnson Burn Wound Assessment Tool.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Intensity of pain. Timepoint: Before and after dressing in the first session. Method of measurement: Visual pain scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Gonabad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-12-24</approval_date>
        <contact_name>Ethnical Committee of Gonabad University of Medical Sciences</contact_name>
        <contact_address>Asian Road Rim, Gonabad University of Medical Sciences Gonabad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
